• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Lactones Delta valerolactones

Introduction to 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid (CAS No. 465-48-5)

4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid, identified by its Chemical Abstracts Service (CAS) number 465-48-5, is a compound of significant interest in the field of organic chemistry and pharmaceutical research. This bicyclic ketone derivative possesses a unique structural framework that has garnered attention for its potential applications in medicinal chemistry and synthetic methodologies.

The molecular structure of 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid consists of a seven-membered oxygen-containing heterocycle fused with a ketone group, further substituted with three methyl groups at the 4th, 7th, and 7th positions respectively. This intricate arrangement imparts distinct chemical properties that make it a valuable intermediate in the synthesis of more complex molecules.

In recent years, the study of such oxygen-rich heterocycles has seen considerable advancement due to their prevalence in bioactive natural products and their utility as scaffolds in drug discovery. The presence of both carbonyl and lactone functionalities in 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid provides multiple points for chemical modification, enabling the construction of diverse pharmacophores.

One of the most compelling aspects of this compound is its role as a precursor in the synthesis of bioactive molecules. Researchers have leveraged its structural motif to develop novel inhibitors targeting various biological pathways. For instance, derivatives of 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid have been explored as potential candidates for their interaction with enzymes involved in metabolic disorders and inflammatory responses.

The synthetic accessibility of 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid has also contributed to its widespread use in academic and industrial laboratories. Its preparation typically involves cyclization reactions that highlight the versatility of bicyclic systems in organic synthesis. The compound’s stability under various reaction conditions further enhances its appeal as a synthetic building block.

Recent studies have demonstrated the utility of 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid in the development of novel therapeutic agents. For example, modifications to its lactone ring have led to the discovery of compounds with promising anti-inflammatory properties. These findings underscore the importance of structural diversity in medicinal chemistry and the potential of heterocyclic compounds like 4,7,7-trimethyl-3-oxyobromo bromo

The pharmacokinetic profile of derivatives derived from 4,7,7-trimethyl-3-oxy-

The pharmacokinetic profile<<<<<<<<<<|

• 13429-83-9((S)-Camphanic Acid)
• 67111-66-4((1R)-(-)-Camphanic acid)
• 19776-79-5(2H-Pyran-2-carboxylicacid, 5-ethyltetrahydro-2,3-dimethyl-6-oxo- (9CI))
• 21416-53-5(Picrotin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)